User menu

Continuous infusion in haemophilia: current practice in Europe.

Bibliographic reference Batorova, A ; Holme, P ; Gringeri, A ; Richards, M ; Hermans, C ; et. al. Continuous infusion in haemophilia: current practice in Europe.. In: Haemophilia, Vol. 18, no.5, p. 753-9 (2012)
Permanent URL http://hdl.handle.net/2078/124947
  1. Brinkhous, Bull N Y Acad Med, 30, 325 (1954)
  2. Hathaway W. E., Christian M. J., Clarke S. L., Hasiba U., Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A, 10.1002/ajh.2830170111
  3. Bona Robert D., Weinstein Ralph A., Weisman Steven J., Bartolomeo Ann, Rickles Frederick R., The use of continuous infusion of factor concentrates in the treatment of hemophilia, 10.1002/ajh.2830320103
  4. Martinowitz U., Schulman S., Gitel S., Horozowski H., Heim M., Taron D., Adjusted dose continuous infusion of factor VIII in patients with haemophilia A, 10.1111/j.1365-2141.1992.tb06951.x
  5. Goldsmith, Blood Coag Fibrinol, 7, 3 (1996)
  6. Martinowitz, Int J Pediatr Hematol/Oncol, 1, 471 (1994)
  7. Schulman Sam, Gitel Sanford, Martinowitz Uri, Stability of factor VIII concentrates after reconstitution, 10.1002/ajh.2830450305
  8. Hay, Blood Coag Fibrinol, 7, 15 (1996)
  9. Batorova Angelika, Martinowitz Uri, Intermittent injections vs. continuous infusion of Factor VIII in haemophilia patients undergoing major surgery, 10.1046/j.1365-2141.2000.02226.x
  10. Campbell P. J., Rickard K. A., Continuous and intermittent infusion of coagulation factor concentrates in patients undergoing surgery: a single centre Australian experience, 10.1111/j.1445-5994.1998.tb02078.x
  11. Tagariello, Davoli, Gajo, De Biasi, Risato, Baggio, Traldi, Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion, 10.1046/j.1365-2516.1999.00335.x
  12. Negrier, Blood Coag Fibrinol, 9, 135 (1998)
  13. Rochat, Mcfadyen, Schwyzer, Gillham, Cruickshank, Continuous infusion of intermediate-purity factor VIII in haemophilia A patients undergoing elective surgery, 10.1046/j.1365-2516.1999.00309.x
  14. Perez Bianco, Haemophilia, 10, PO38 (2004)
  15. Dingli D., Gastineau D. A., Gilchrist G. S., Nichols W. L., Wilke J. L., Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates, 10.1046/j.1365-2516.2002.00650.x
  16. Hoots W. K., Leissinger C., Stabler S., Schwartz B. A., White G., Dasani H., Massion C., Negrier C., Schindel F., Schulman S., Continuous intravenous infusion of a plasma-derived factor IX concentrate (MononineR) in haemophilia B, 10.1046/j.1365-2516.2003.00721.x
  17. Srivastava, Thromb Haemost (2001)
  18. BIDLINGMAIER C., DEML M.-M., KURNIK K., Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections, 10.1111/j.1365-2516.2006.01217.x
  19. Batorova Angelika, Martinowitz Uri, Continuous infusion of coagulation factors: current opinion : , 10.1097/01.moh.0000239701.32674.e0
  20. Stieltjes N., Altisent C., Auerswald G., Negrier C., Pouzol P., Reynaud J., Roussel-Robert V., Savidge G. F., Villar A., Schulman S., Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience, 10.1111/j.1365-2516.2004.01013.x
  21. Négrier, Thromb Haemost, 100, 217 (2008)
  22. MARTINOWITZ U., LUBOSHITZ J., BASHARI D., RAVID B., GORINA E., REGAN L., STASS H., LUBETSKY A., Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia, 10.1111/j.1365-2516.2008.01978.x
  23. Mulcahy R., Walsh M., Scully M.-F., Retrospective audit of a continuous infusion protocol for haemophilia A at a single haemophilia treatment centre, 10.1111/j.1365-2516.2005.01084.x
  24. White, Cotter, Byrne, O'Shea, Smith, High responding factor VIII inhibitors in mild Haemophilia - is there a link with recent changes in clinical practice?, 10.1046/j.1365-2516.2000.00390.x
  25. Batorova A., Martinowitz U., Continuous infusion of coagulation factors, 10.1046/j.1365-2516.2002.00635.x
  26. Sharathkumar A., Lillicrap D., Blanchette V. S., Kern M., Leggo J., Stain A. M., Brooker L., Carcao M. D., Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A : Inhibitors in mild hemophilia A following continuous infusion of factor VIII, 10.1046/j.1538-7836.2003.00230.x
  27. AUER CH, OLDENBURG J., DEPKA M., ESCURIOLA-ETTINGHAUSEN C., KURNIK K., LENK H., SCHARRER I., Inhibitor Development in Patients with Hemophilia A after Continuous Infusion of FVIII Concentrates, 10.1196/annals.1361.094
  28. ECKHARDT C.L., MENKE L.A., VAN OMMEN C.H., VAN DER LEE J.H., GESKUS R.B., KAMPHUISEN P.W., PETERS M., FIJNVANDRAAT K., Intensive peri-operative use of factor VIII and the Arg593→Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A, 10.1111/j.1538-7836.2009.03357.x
  29. Osip, Haemophilia, 12, 05PO111 (2006)
  30. Schulman S., Continuous infusion, 10.1046/j.1365-2516.2003.00765.x
  31. HERMANS C., ALTISENT C., BATOROVA A., CHAMBOST H., DE MOERLOOSE P., KARAFOULIDOU A., KLAMROTH R., RICHARDS M., WHITE B., DOLAN G., , Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations, 10.1111/j.1365-2516.2008.01950.x
  32. Nishiya, J Thromb Haemost, 9, 929 (2011)
  33. STRAUSS T., LUBETSKY A., RAVID B., BASHARI D., LUBOSHITZ J., LALEZARI S., MISGAV M., MARTINOWITZ U., KENET G., Recombinant factor concentrates may increase inhibitor development: a single centre cohort study : EARLY EXPOSURE TO RECOMBINANT FACTOR INCREASE INHIBITOR DEVELOPMENT, 10.1111/j.1365-2516.2010.02464.x
  34. Pautard, J Thromb Haemost, 9 (2011)
  35. Martinowitz, Blood Coag Fibrinol, 7, 27 (1996)
  36. Mcleod, Walker, Zheng, Hayward, Loss of factor VIII activity during storage in PVC containers due to adsorption, 10.1046/j.1365-2516.2000.00382.x
  37. Fernandez Maximilian, Yu Tabitha, Bjornson Erik, Luu Huong, Spotts Gerald, Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion : , 10.1097/01.mbc.0000220236.92219.08
  38. DiMichele Donna M., Lasak Martin E., Miller Connie H., In vitro factor VIII recovery during the delivery of ultra-pure factor VIII concentrate by continuous infusion, 10.1002/(sici)1096-8652(199602)51:2<99::aid-ajh1>3.0.co;2-1
  39. REVEL-VILK S., BLANCHETTE V. S., SCHMUGGE M., CLARK D. S., LILLICRAP D., RAND M. L., In vitroandin vivostability of diluted recombinant factor VIII for continuous infusion use in haemophilia A, 10.1111/j.1365-2516.2009.02103.x
  40. Escobar M. A., Treatment on demand -in vivo dose finding studies, 10.1046/j.1365-2516.2003.00761.x
  41. Srivastava Alok, Dose and response in haemophilia - optimization of factor replacement therapy, 10.1111/j.1365-2141.2004.05110.x
  42. Schulman, Haemophilia, 10, 35 (2004)
  43. Srivastava, Chandy, Sunderaj, Lee, Daniel, Dennison, Nair, Mathews, Anderson, Nair, Moses, Sudarsanam, Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia, 10.1046/j.1365-2516.1998.00161.x
  44. Scharrer I., , Experience with KOGENATER Bayer in surgical procedures, 10.1046/j.1351-8216.2001.00132.x
  45. Scharrer I., Brackmann H.-H., Sultan Y., Abshire T., Gazengel C., Ragni M., Gorina E., Vosburgh E., Kellermann E., Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A, 10.1046/j.1365-2516.2000.00432.x
  46. Mishra V., Tjonnfjord G. E., Paus A. C., Vaaler S., Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure, 10.1046/j.1365-2516.2002.00691.x
  47. Kasper Carol K., Hematologic Management of Hemophilia A for Surgery, 10.1001/jama.1985.03350330077026
  48. Hay, Thromb Haemost, 79, 762 (1998)
  49. Carcao M. D., More on: intensive factor VIII exposure and inhibitor development in mild hemophilia A, 10.1111/j.1538-7836.2004.00679.x
  50. Santagostino Elena, Mancuso Maria Elisa, Rocino Angiola, Mancuso Giacomo, Mazzucconi Maria Gabriella, Tagliaferri Annarita, Messina Maria, Mannucci Pier Mannuccio, Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study, 10.1111/j.1365-2141.2005.05605.x
  51. GOUW S. C., VAN DEN BERG H. M., LE CESSIE S., VAN DER BOM J. G., Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A, 10.1111/j.1538-7836.2007.02595.x
  52. Gouw S. C., van der Bom J. G., Marijke van den Berg H., , Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study, 10.1182/blood-2006-11-056291
  53. CHALMERS E. A., BROWN S. A., KEELING D., LIESNER R., RICHARDS M., STIRLING D., THOMAS A., VIDLER V., WILLIAMS M. D., YOUNG D., , Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A, 10.1111/j.1365-2516.2006.01418.x
  54. ter, J Thromb Haemost, 6 (2008)
  55. Ghosh K., Jijina F., Shetty S., Madkaikar M., Mohanty D., First-time development of FVIII inhibitor in haemophilia patients during the postoperative period, 10.1046/j.1365-2516.2002.00687.x
  56. Auerswald, Haemophilia, 16, 30 (2010)
  57. OLDENBURG J., PAVLOVA A., Genetic risk factors for inhibitors to factors VIII and IX, 10.1111/j.1365-2516.2006.01361.x
  58. COPPOLA A., SANTORO C., TAGLIAFERRI A., FRANCHINI M., DI MINNO G., Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies, 10.1111/j.1365-2516.2009.02175.x
  59. Astermark Jan, Overview of Inhibitors, 10.1053/j.seminhematol.2006.03.006
  60. Fijnvandraat, Blood, 89, 4371 (1997)
  61. Lee C. A., Kessler C. M., Varon D., Martinowitz U., Heim M., HAY C. R. M., Factor VIII inhibitors in mild and moderate-severity haemophilia A, 10.1046/j.1365-2516.1998.440558.x
  62. FRANCHINI M., GIRELLI D., OLIVIERI O., CASTAMAN G., LIPPI G., POLI G., SALVAGNO G. L., TAGARIELLO G., GIUFFRIDA A., DE GIRONCOLI M., MORFINI M., BERNTORP E., GANDINI G., Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A, 10.1111/j.1365-2516.2006.01297.x
  63. Liu, Thromb Haemost, 87, 273 (2002)
  64. d’Oiron Roseline, Volot F., Reynaud J., Peerlinck K., Goudemand J., Guérois C., Rothschild C., Chambost H., Borel-Derlon A., Roussel-Robert V., Marquès-Verdier A., Lienhart A., Berthier A.M., Moreau P., Lambert T., Impact of Choice of Treatment for Bleeding Episodes on Inhibitor Outcome in Patients With Mild/Moderate Hemophilia A and Inhibitors, 10.1053/j.seminhematol.2005.11.002
  65. CALVEZ T., LAURIAN Y., GOUDEMAND J., Inhibitor incidence with recombinant vs. plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies, 10.1111/j.1538-7836.2008.02852.x
  66. IORIO A., HALIMEH S., HOLZHAUER S., GOLDENBERG N., MARCHESINI E., MARCUCCI M., YOUNG G., BIDLINGMAIER C., BRANDAO L. R., ETTINGSHAUSEN C. E., GRINGERI A., KENET G., KNÖFLER R., KREUZ W., KURNIK K., MANNER D., SANTAGOSTINO E., MANNUCCI P. M., NOWAK-GÖTTL U., Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review : Inhibitor rate after plasma-derived or recombinant FVIII concentrates, 10.1111/j.1538-7836.2010.03823.x
  67. Powell Jerry, Recombinant factor VIII in the management of hemophilia A: current use and future promise, 10.2147/tcrm.s4412
  68. WINDYGA J., RUSEN L., GRUPPO R., O’BRIEN A. C., KELLY P., ROTH D. A, ARKIN S., BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study : BDDRFVIII FOR SURGICAL HAEMOSTASIS IN HAEMOPHILIA A, 10.1111/j.1365-2516.2010.02239.x
  69. TAKEDANI H., Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII : CONTINUOUS INFUSION DURING TJA, 10.1111/j.1365-2516.2010.02244.x